Tesamorelin is one of the few compounds on this site with a real, standing FDA approval. That approval is also much narrower than the way tesamorelin gets discussed in most research-peptide circles — and getting that distinction right is the entire point of this guide.
What Is Tesamorelin?
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue, sold under the brand names Egrifta and Egrifta WR.
Mechanism of Action
Tesamorelin doesn't act on fat tissue directly — it works two steps upstream, by restoring a signal the body normally sends to itself. Growth hormone (GH) is released from the pituitary gland in pulses, triggered by GHRH from the hypothalamus. Tesamorelin is a stabilized version of that same GHRH signal, so it amplifies the body's own pulsatile GH release rather than delivering GH directly. That distinction matters for two reasons:
- It preserves the natural feedback loop. GH released this way still triggers the liver to produce IGF-1, which signals back to suppress further GH release — the same brake that keeps GH regulated in healthy physiology. Direct GH injection can override that feedback; a GHRH analogue is designed to work within it.
- GH's downstream effect on fat is the actual lipolytic step. Once GH reaches fat tissue, it stimulates hormone-sensitive lipase, the enzyme that breaks down stored fat into free fatty acids. Visceral fat — the metabolically active fat around organs, as opposed to fat just under the skin — is disproportionately responsive to this GH-driven lipolysis, which is why the drug's effect concentrates there.
One honest caveat worth keeping: a clinical-policy review of the approval data still calls the full mechanism "unclear" beyond this GH/IGF-1 chain — the GHRH-to-GH-to-visceral-fat pathway is well-supported, but not every step is fully mapped.
FDA Approval — Read the Indication Carefully
Real approval, narrow scope. Tesamorelin is FDA-approved as Egrifta (2010) and the reformulated Egrifta WR (approved March 2025) — but specifically for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. It is not approved for general-population body composition or weight loss.
Approval was supported by trials showing reductions in visceral adipose tissue, triglycerides, and non-HDL cholesterol, plus increases in lean body mass — in the HIV-lipodystrophy population specifically. Those results don't automatically generalize to a healthy adult using it for general fat loss; that's simply a different population than the one studied.
Regulatory Status for Research Use
What's sold by research-peptide vendors as tesamorelin is not the approved Egrifta pharmaceutical product — it's compounded material intended for research use, outside the approved indication and outside FDA's review of Egrifta's manufacturing and formulation.
Checked directly against FDA's bulk drug substances list for compounding (fetched July 2026): tesamorelin does not appear in either the active Category 2 table or the nominated-but-withdrawn table.
Where to Source Tesamorelin for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the Tesamorelin product page →Frequently Asked Questions
Is tesamorelin FDA-approved?
Yes, but only for one narrow indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (brand names Egrifta / Egrifta WR). It is not approved for general fat loss or body composition.
Can I use tesamorelin for general fat loss?
That use falls outside the approved indication. What's sold as tesamorelin by research vendors is a research compound, not the approved Egrifta pharmaceutical product, and hasn't been evaluated by FDA for that purpose.
References
1. EATG / Theratechnologies. "FDA approval for EGRIFTA WR (tesamorelin F8)," March 2025. eatg.org
2. Molina Healthcare Clinical Policy 131 (Egrifta/Tesamorelin), citing FDA prescribing information and NDA review documents. molinahealthcare.com
3. EGRIFTA WR official HCP site — indication statement. hcp.egriftawr.com
4. Stanley TL, Grinspoon SK. "Effects of growth hormone-releasing hormone on visceral fat..." sciencedirect.com
5. Vijayakumar A, et al. "Biological effects of growth hormone on carbohydrate and lipid metabolism," 2010. sciencedirect.com
6. FDA. "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." fda.gov
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.